Pregnancy and Cardiometabolic Health: Gestational Diabetes, GLP-1s, and What Every Pregnant Patient Needs to Know

What Is Gestational Diabetes and Why Does It Develop?

Gestational diabetes mellitus (GDM) is glucose intolerance that begins or is first detected during pregnancy. Placental hormones, including human placental lactogen, progesterone, and cortisol, progressively blunt insulin signaling starting around week 20. In women whose pancreatic beta-cell reserve is sufficient, compensatory hyperinsulinemia keeps glucose normal. When it is not, GDM develops.

The American Diabetes Association's 2024 Standards of Medical Care in Diabetes defines GDM as a fasting plasma glucose of 92 mg/dL or higher, a 1-hour post-load value of 180 mg/dL or higher, or a 2-hour value of 153 mg/dL or higher on a 75 g OGTT performed at 24 to 28 weeks [1]. Pre-existing undiagnosed type 2 diabetes can masquerade as GDM; an HbA1c at or above 6.5% in the first trimester signals pre-gestational disease rather than true GDM [1].

Risk factors include pre-pregnancy BMI at or above 30 kg/m², prior GDM, polycystic ovary syndrome, a first-degree relative with type 2 diabetes, and non-white ethnicity. The HAPO study (N=23,316 mother-infant pairs) established that even glucose values below the GDM diagnostic threshold are continuously associated with birth weight above the 90th percentile, primary cesarean delivery, and neonatal hypoglycemia, meaning no single "safe" glucose level exists below which fetal risk disappears entirely [2].

Untreated GDM carries real consequences. Macrosomia, defined as birth weight above 4 to 000 g, occurs in 15 to 45 percent of untreated cases, and the rate of shoulder dystocia rises proportionally [3]. Neonatal hypoglycemia, hyperbilirubinemia, and admission to the neonatal intensive care unit are each significantly more frequent when maternal glucose is uncontrolled.

How Is GDM Diagnosed and Monitored?

Two diagnostic strategies remain in use in the United States. ACOG still endorses the two-step Carpenter-Coustan approach: a 50 g glucose challenge test at 24 to 28 weeks, followed by a 100 g OGTT if the 1-hour value meets or exceeds 135 to 140 mg/dL. The one-step strategy recommended by IADPSG and incorporated into ADA 2024 guidelines uses a single fasting 75 g OGTT with three measurement points [1].

ACOG's 2018 Practice Bulletin No. 190 states: "The two-step approach is endorsed by ACOG because of its established sensitivity and specificity in identifying women and neonates at risk of adverse outcomes, and because it is well-validated in U.S. populations" [4].

Once GDM is diagnosed, self-monitoring of blood glucose (SMBG) typically involves four daily checks: fasting and one to two hours after each meal. Most clinicians target fasting glucose below 95 mg/dL, 1-hour postprandial glucose at or below 140 mg/dL, and 2-hour postprandial glucose at or below 120 mg/dL. Continuous glucose monitoring is gaining traction in pregnancy, though strong outcome data specific to GDM pregnancies are still emerging.

Women with pre-existing type 1 or type 2 diabetes require tighter monitoring and individualized HbA1c targets, generally below 6 to 6.5 percent during pregnancy, while avoiding hypoglycemia. The CONCEPTT trial (N=215) showed that real-time continuous glucose monitoring in pregnant women with type 1 diabetes reduced the rate of large-for-gestational-age neonates from 69 to 53 percent (P<0.001) and cut neonatal intensive care admissions from 45 to 27 percent [5].

Dietary and Lifestyle Management of GDM

Medical nutrition therapy is the foundation. It works in roughly 70 to 85 percent of GDM cases without any medication. The objective is to achieve target glucose values while providing adequate calories for fetal growth and avoiding ketosis.

A moderate carbohydrate restriction, typically 35 to 45 percent of total calories from complex, high-fiber carbohydrates, distributed across three meals and two to three snacks per day, prevents the glucose spikes that drive macrosomia. Refined grains, sugary beverages, and high-glycemic fruits should be replaced with legumes, non-starchy vegetables, whole oats, and lower-glycemic fruits such as berries. Total daily carbohydrate intake generally ranges from 175 to 220 g, the minimum recommended by the Institute of Medicine to support fetal brain development.

Aerobic exercise at moderate intensity for 30 minutes on most days of the week improves peripheral insulin sensitivity measurably. A 2016 meta-analysis in Diabetologia (13 trials, N=709) found that exercise interventions reduced postprandial glucose by approximately 0.5 mmol/L and lowered the need for insulin initiation by 40 percent relative to standard care alone [6].

Weight gain recommendations depend on pre-pregnancy BMI. Women with a pre-pregnancy BMI of 18.5 to 24.9 kg/m² should gain 11.5 to 16 kg total; those with a BMI of 30 kg/m² or higher, 5 to 9 kg total, per the 2009 Institute of Medicine guidelines still referenced in current practice [7].

When Medication Becomes Necessary: Insulin and Oral Agents

Pharmacotherapy is added when glucose targets are not met after one to two weeks of optimized medical nutrition therapy. Insulin remains the preferred agent because it does not cross the placenta in clinically significant amounts and has the longest safety record in pregnancy.

Human NPH insulin and regular insulin are both FDA-approved with extensive safety data. The rapid-acting analogs insulin aspart (NovoLog) and insulin lispro (Humalog) are also widely used and supported by ADA and ACOG guidance. Insulin detemir (Levemir) carries FDA Category B classification in pregnancy; insulin glargine (Lantus) is used off-label with a reasonable safety profile in observational data, though it does not carry a formal pregnancy indication.

Metformin is frequently prescribed globally as an oral alternative. The MiG trial (N=751) found metformin non-inferior to insulin for composite neonatal outcomes, including hypoglycemia and respiratory distress [8]. However, metformin crosses the placenta freely, reaching fetal concentrations approximately 50 percent of maternal levels, and the long-term metabolic implications for offspring remain under study. ACOG acknowledges metformin as an acceptable alternative when patients decline insulin or adherence is a concern.

Glyburide has largely fallen out of favor due to neonatal hypoglycemia rates roughly twice those seen with insulin in randomized data.

GLP-1 Receptor Agonists and Pregnancy: A Hard Stop

GLP-1 receptor agonists, including semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), tirzepatide (Mounjaro, Zepbound), and dulaglutide (Trulicity), are contraindicated in pregnancy. This is not a soft caution. Animal reproductive toxicology studies showed reduced fetal weight, skeletal abnormalities, and increased early pregnancy loss at exposures below or similar to human therapeutic doses [9]. Human data are sparse but consistent with harm signals.

The FDA label for semaglutide states directly: "Discontinue OZEMPIC when pregnancy is detected. Based on animal data, may cause fetal harm" [9]. Given that semaglutide's half-life is approximately one week and that pharmacologically meaningful tissue concentrations persist for four to five half-lives, Novo Nordisk recommends discontinuing semaglutide at least two months before a planned conception attempt. Tirzepatide carries a similar recommendation based on its four-to-five-day half-life.

Women of reproductive age on GLP-1 agents should use effective contraception and have a clear plan documented in the chart. Because these drugs reduce gastric emptying and can alter absorption of oral contraceptives, barrier methods or IUDs are more reliable than combined oral pills in this population.

The HealthRX clinical team uses the following decision framework for GLP-1 patients of reproductive age:

1. At GLP-1 initiation: document reproductive intent, current contraceptive method, and date of last menstrual period.
2. At each quarterly visit: re-confirm contraceptive use and update reproductive intent.
3. If conception is planned: discontinue GLP-1 at least 8 weeks before stopping contraception; document the switch date.
4. If pregnancy is detected while on a GLP-1: discontinue immediately, notify the prescribing team within 24 hours, and refer to maternal-fetal medicine if GDM or pre-existing diabetes is present.
5. Postpartum: reassess GLP-1 candidacy at the 6-week visit; do not restart during active breastfeeding given the absence of human lactation safety data.

Preeclampsia, Hypertension, and Cardiometabolic Risk in Pregnancy

Hypertensive disorders of pregnancy, including gestational hypertension, preeclampsia, and eclampsia, complicate 5 to 10 percent of all pregnancies globally [10]. Preeclampsia is not simply a blood pressure problem. It involves widespread endothelial dysfunction, activation of the renin-angiotensin-aldosterone system, and systemic inflammation, all of which overlap substantially with the pathophysiology of atherosclerosis and metabolic syndrome.

A 2019 statement from the American Heart Association classified preeclampsia as an independent, sex-specific cardiovascular risk factor [11]. Women with a history of preeclampsia carry a 2-fold elevated risk of coronary heart disease, a 1.8-fold elevated risk of stroke, and a 3 to 4-fold elevated risk of heart failure compared with women whose pregnancies were normotensive [11].

Aspirin 81 mg/day started between 12 and 16 weeks of gestation reduces the incidence of preterm preeclampsia by approximately 62 percent in high-risk women, per a 2017 NEJM trial (N=1,776) by Rolnik et al. [12]. ACOG now recommends low-dose aspirin for women with one high-risk factor (chronic hypertension, diabetes, history of preeclampsia, multifetal gestation, chronic kidney disease) or more than one moderate-risk factor.

Blood pressure targets in pregnancy are evolving. The CHIPS trial (N=987) found that "tight" control targeting a diastolic below 85 mmHg versus "less tight" control (diastolic below 100 mmHg) did not increase adverse perinatal outcomes and reduced severe hypertension by 50 percent [13]. ACOG's current guidance recommends treating blood pressure at or above 160/110 mmHg acutely and considers treatment at 140/90 mmHg in women with chronic hypertension based on the 2022 CHAP trial findings.

Safe antihypertensives in pregnancy include labetalol, nifedipine extended-release, and methyldopa. ACE inhibitors, ARBs, and direct renin inhibitors are contraindicated throughout pregnancy due to fetal renal toxicity.

Thyroid, Lipids, and Other Cardiometabolic Considerations

The thyroid gland expands its hormone output by roughly 50 percent during pregnancy to meet fetal demand. Hypothyroidism, present in approximately 2 to 3 percent of pregnant women, is associated with gestational hypertension, placental abruption, and impaired fetal neurological development [14]. TSH should be maintained below 2.5 mIU/L in the first trimester and below 3.0 mIU/L thereafter. Levothyroxine dose typically increases by 25 to 30 percent as soon as pregnancy is confirmed; the standard clinical instruction is to take two extra levothyroxine doses per week starting at a positive pregnancy test.

Lipid metabolism shifts considerably during pregnancy. Total cholesterol, LDL, and triglycerides all rise, with triglycerides potentially doubling by the third trimester. This is physiologically normal and necessary for placental steroidogenesis and fetal membrane development. Statins are contraindicated in pregnancy and must be discontinued before conception. Fibrates are generally avoided in the first trimester. Women with familial hypercholesterolemia who require lipid-lowering therapy during pregnancy may be candidates for LDL apheresis under specialist guidance.

Long-Term Cardiometabolic Risk After GDM: The Decade That Follows Delivery

GDM resolves at delivery for most women, but it leaves a permanent metabolic fingerprint. The CARDIA study and other longitudinal cohorts show that women with prior GDM have approximately a 7-fold higher lifetime risk of developing type 2 diabetes compared to women with normoglycemic pregnancies [15]. Fifty percent of women with GDM will develop type 2 diabetes within 10 years if they do not adopt preventive lifestyle measures.

Postpartum testing is therefore not optional. The ADA recommends a 75 g OGTT at 4 to 12 weeks postpartum for all women with GDM, followed by screening every 1 to 3 years thereafter [1]. HbA1c alone is less sensitive than the OGTT in the postpartum period because iron-deficiency anemia from delivery can falsely lower HbA1c values.

The Diabetes Prevention Program (DPP) trial (N=3,234) demonstrated that intensive lifestyle intervention reduced progression from prediabetes to type 2 diabetes by 58 percent over 2.8 years, and metformin reduced it by 31 percent [16]. Women with prior GDM are ideal DPP candidates; referral to a CDC-recognized DPP program should be part of the postpartum care plan for every GDM pregnancy.

Breastfeeding independently reduces maternal diabetes risk. Women who breastfeed for 12 months or longer have a 30 percent lower rate of type 2 diabetes after GDM in observational data [17]. Clinicians should support and encourage breastfeeding both for the infant's benefit and the mother's own long-term metabolic health.

Cardiometabolic Health in Athletes Who Are Pregnant

Physically active women and competitive athletes face a different clinical profile during pregnancy. High training volumes before conception are associated with lower GDM risk, though rapid deconditioning during early pregnancy due to nausea and fatigue can mask underlying insulin resistance. Athletes who stop training abruptly may show unexpected glucose dysregulation on OGTT screening despite a lean phenotype.

Current ACOG guidance supports continuation of vigorous exercise throughout uncomplicated pregnancies [18]. Women who were running more than 30 miles per week before pregnancy may continue running into the third trimester with appropriate pelvic floor monitoring. Absolute contraindications to exercise in pregnancy include placenta previa after 26 weeks, ruptured membranes, and preeclampsia.

Energy availability is a specific concern in pregnant athletes. Relative Energy Deficiency in Sport (RED-S) during pregnancy can restrict fetal growth. The IOC's 2018 consensus on RED-S notes that energy availability below 45 kcal/kg of fat-free mass per day impairs bone metabolism and reproductive hormone function; the same threshold appears relevant in pregnancy [19]. Athletes with suspected RED-S during pregnancy should be referred to a sports dietitian with prenatal expertise.

Older Maternal Age and Cardiometabolic Risk

Women who conceive after age 35, a population now representing roughly 20 percent of U.S. births, face compounded cardiometabolic risk. GDM prevalence increases steeply with age: roughly 4.4 percent at ages 20 to 24 versus approximately 13.4 percent at ages 40 to 44 in population data [20]. Beta-cell reserve declines with age, making compensation for pregnancy-induced insulin resistance less effective.

Chronic hypertension is also more prevalent in older mothers, raising the baseline risk for preeclampsia. Women over 40 have roughly a 2-fold higher risk of preeclampsia compared with women aged 25 to 29 [20]. Preconception counseling at age 35 or older should include a thorough cardiometabolic assessment: fasting glucose or HbA1c, lipid panel, blood pressure review, and BMI evaluation.